Entrada Therapeutics, Inc. (TRDA) return on invested capital (ROIC)
Entrada Therapeutics, Inc. (TRDA) earned a return on invested capital of -203.3% in fiscal 2025 (the year ended December 31, 2025). That is 271.6 percentage points lower than the 68.4% of fiscal 2024. Figures as of 17 Nov 2026, 23:49 UTC, from the company's filings with the SEC and Yahoo Finance.
Key facts
- Return on invested capital, fiscal 2025
- -203.3%
- Change on fiscal 2024
- −271.6 pts
- Highest on record
- 68.4%fiscal 2024
- Lowest on record
- -203.3%fiscal 2025
- Fiscal years on record
- 32022–2025
Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.
Entrada Therapeutics, Inc. return on invested capital (ROIC), in more detail
Across the 3 fiscal years on record (2022–2025), the highest was 68.4% in fiscal 2024 and the lowest -203.3% in fiscal 2025.
Return on invested capital by fiscal year
Entrada Therapeutics, Inc. return on invested capital (ROIC), year by year
| Fiscal year | Return on invested capital | Change | Year ended |
|---|---|---|---|
| 2025 | -203.3% | 271.6 pts down | |
| 2024 | 68.4% | — | |
| 2022 | -154.3% | — |
Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
Return on invested capital is operating income after tax divided by the capital in the business — debt plus equity minus cash — using the company's own tax rate where it is plausible and 21% otherwise, and shown only for the fiscal years in which cash is counted one way.
How to read it
It measures how well the business turns capital into profit whoever supplied it; a figure above the cost of that capital, roughly 8–10%, means growth creates value.
Entrada Therapeutics, Inc., figure by figure
- Entrada Therapeutics, Inc. market cap
- Entrada Therapeutics, Inc. revenue
- Entrada Therapeutics, Inc. earnings
- Entrada Therapeutics, Inc. earnings per share (EPS)
- Entrada Therapeutics, Inc. P/E ratio
- Entrada Therapeutics, Inc. P/S ratio
- Entrada Therapeutics, Inc. P/B ratio
- Entrada Therapeutics, Inc. free cash flow
- Entrada Therapeutics, Inc. operating margin
- Entrada Therapeutics, Inc. dividend
- Entrada Therapeutics, Inc. shares outstanding
- Entrada Therapeutics, Inc. total debt
- Entrada Therapeutics, Inc. cash on hand
- Entrada Therapeutics, Inc. total assets
- Entrada Therapeutics, Inc. return on equity (ROE)
Entrada Therapeutics, Inc. (TRDA) overview: price, valuation and scorecard
Entrada Therapeutics, Inc. return on invested capital (ROIC): questions and answers
What is Entrada Therapeutics, Inc.'s return on invested capital?
Entrada Therapeutics, Inc. (TRDA) earned a return on invested capital of -203.3% in fiscal 2025 (the year ended December 31, 2025). That is 271.6 percentage points lower than the 68.4% of fiscal 2024.
What are the highest and lowest return on invested capital figures on record for Entrada Therapeutics, Inc.?
Across the 3 fiscal years on record (2022–2025), the highest was 68.4% in fiscal 2024 and the lowest -203.3% in fiscal 2025.
How is Entrada Therapeutics, Inc.'s return on invested capital calculated?
Return on invested capital is operating income after tax divided by the capital in the business — debt plus equity minus cash — using the company's own tax rate where it is plausible and 21% otherwise, and shown only for the fiscal years in which cash is counted one way.
Fiscal years are named for the calendar year they end in.
Learn: return on invested capital (ROIC)
All stocks guides →- Return on invested capital (ROIC) vs ROE and ROA
Return on invested capital (ROIC) is after-tax operating profit divided by the money tied up in the business: debt plus equity, less cash. A company earning $15 million after tax on $100 million of invested capital has a 15% ROIC. Unlike return on equity, it does not rise just because a company borrows more.
- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
Cite this page
Funkfolio, “Entrada Therapeutics, Inc. (TRDA) return on invested capital (ROIC)”, data as of 17 November 2026. https://funkfolio.com/stock/TRDA/roic
Underlying data: the company's filings with the SEC and Yahoo Finance.